Senzagen AB logo

Senzagen AB (SENZA)

Market Open
10 Aug, 15:25
XSTO XSTO
kr
5. 32
+0.04
+0.7576%
kr
175.54M Market Cap
- P/E Ratio
- Div Yield
5,605 Volume
-0.4 Eps
kr 5.28
Previous Close
Add Transaction
Day Range
5.12 5.7
Year Range
4.6 6.84
Want to track SENZA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SENZA trading today higher at kr5.32, an increase of 0.7576% from yesterday's close, completing a monthly decrease of -1.845% or -kr0.1. Over the past 12 months, SENZA stock lost -12.2112%.
SENZA is not paying dividends to its shareholders.
The last earnings report, released on Feb 13, 2025, missed the consensus estimates by -0.1589%. On average, the company has fell short of earnings expectations by -0.0796%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

SENZA Chart

People also search for

Enrad AB
kr 8.5
-1.1628%
Poolia AB
kr -
-
Freja eID Group AB
kr 21.9
-1.3514%
Teneo AI AB
kr 0.07
-14.7815%
Invoicery Group AB
kr 6.95
-0.7143%

Senzagen AB (SENZA) FAQ

What is the stock price today?

The current price is kr5.32.

On which exchange is it traded?

Senzagen AB is listed on XSTO.

What is its stock symbol?

The ticker symbol is SENZA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 175.54M.

Has Senzagen AB ever had a stock split?

No, there has never been a stock split.

Senzagen AB Profile

Professional Services Industry
Industrials Sector
Mr. Peter Nahlstedt CEO
XSTO Exchange
SE0010219626 ISIN
Sweden Country
33 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

SenzaGen AB is a pioneering company incorporated in 2010, based in Lund, Sweden, specializing in the development of non-animal test methods for assessing the allergenicity of substances. Leveraging innovative in vitro techniques, it provides a range of tests aimed at identifying chemical sensitizers for skin and respiratory paths, as well as determining their potency. In its commitment to replace traditional animal testing methods, SenzaGen collaborates with notable partners, including the Research Institute for Fragrance Materials, to advance the science of allergen detection. This is part of its broader effort to offer alternatives that are not only humane but also precise and reliable, meeting the needs of various industries including pharmaceuticals, chemicals, and medical devices.

Products and Services

  • GARDskin – This in vitro test stands out for its ability to identify potential chemical skin sensitizers without animal testing. It's a cornerstone technology that reflects SenzaGen's commitment to innovative, ethical research practices.
  • GARDpotency – An in vitro add-on test to GARDskin, GARDpotency classifies the potency of identified sensitizers, providing additional qualitative data crucial for safety assessments.
  • GARDskin Dose-response – Offering a more nuanced analysis, this in vitro test quantifies the skin sensitizing potency of chemicals, presenting a significant advancement in the precision of allergenicity assessments.
  • GARDair – Expanding its scope beyond skin sensitization, SenzaGen introduces an in vitro method for identifying chemical respiratory sensitizers, addressing a critical aspect of occupational and consumer health.
  • GARDskin medical device – Specifically designed for the medical devices sector, this in vitro skin sensitization test caters to the unique requirements of the industry, ensuring that materials are safe and non-irritating for patient use.
  • Additional Testing Services – Beyond its flagship products, SenzaGen also offers a suite of services for irritation, corrosion, and absorption testing, making it a comprehensive provider for allergenicity and safety testing.

The company extends its reach through a network of license partners and distributors, enabling it to serve a global clientele effectively. This strategy not only maximizes the accessibility of its unique testing solutions but also underscores SenzaGen's role as a leader in the field of non-animal testing for allergenicity assessment.

Contact Information

Address: Building 401
Phone: 46 4 62 75 62 00